First identified in 2012, Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel virus that can cause acute respiratory distress syndrome (ARDS), multiorgan failure, and death, with a case fatality rate of~35%. An animal model that supports MERS-CoV infection and causes severe lung disease is useful to study pathogenesis and evaluate therapies and vaccines. The murine dipeptidyl peptidase 4 (Dpp4) protein is not a functional receptor for MERS-CoV; thus, mice are resistant to MERS-CoV infection. We generated human DPP4 knock-in (hDPP4 KI) mice by replacing exons 10-12 at the mouse Dpp4 locus with exons 10-12 from the human DPP4 gene. The resultant human DPP4 KI mice are permissive to MERS-CoV (HCoV-EMC/2012 strain) infection but develop no disease. To generate a mouse model with associated morbidity and mortality from respiratory disease, we serially passaged HCoV-EMC/2012 strain in the lungs of young hDPP4 KI mice. After 30 in vivo passages, an adapted virus clone was isolated and designated MERS MA 6.1.2. This virus clone produced significantly higher titers than the parental clone in the lungs of hDPP4 KI mice and caused diffuse lung injury and a fatal respiratory infection. In this chapter, we will describe in detail the procedures used to mouse adapt MERS-CoV by serial passage of the virus in lungs. We also describe the methods used to isolate virus clones and characterize virus infection.
Introduction
Middle East respiratory syndrome (MERS) is a fatal respiratory illness that first appeared on the Saudi Arabian Peninsula in mid-2012. It is caused by a novel betacoronavirus, MERS coronavirus (MERS-CoV) [1] . Shortly after the identification of the virus, its receptor dipeptidyl peptidase 4 (DPP4) was discovered [2] . As of September 2019, the World Health Organization (WHO) has reported 2468 laboratory-confirmed cases of MERS in 27 countries, including 851 associated deaths (fatality rate: 35%). MERS-CoV does not currently have pandemic potential [3] [4] [5] . However, MERS-CoV is still epidemic in the Middle East and remains a cause for significant concern due to the potential spread by global travel as demonstrated by the outbreak in South Korea in 2015 [6] [7] [8] .
To date, there are only two published reports on autopsy findings from subjects who died from MERS [9, 10] and our understanding of MERS-CoV pathogenesis in humans is still limited. Animal models are useful for the study of viral diseases and play an important role in the investigation of pathogenesis and evaluation of antiviral therapies and vaccines. An ideal animal model should be permissive to the viral infection and develop disease and pathology with similarities to that observed in humans. MERS-CoV infection has been evaluated in two nonhuman primate (NHP) models, the rhesus macaque and common marmoset [11] [12] [13] [14] [15] . Both species are susceptible to MERS-CoV infection. However, MERS-CoV caused only a transient lower respiratory tract infection without mortality in rhesus macaques [11] [12] [13] . In common marmosets, the consequences of MERS-CoV infection are controversial. Falzarano et al. reported the common marmoset reproduced several features of MERS-CoV infection in humans including progressive severe pneumonia [15] , while another group observed only mild to moderate nonlethal respiratory disease following MERS-CoV infection [14] . Thus, the common marmoset is potentially a model to study pathogenesis and evaluate antiviral therapies and vaccines. However, NHPs are expensive, their availability limited, and their use may raise ethical concerns. In contrast, small animal models provide advantages over NHPs, including reduced cost, availability in large numbers, ease of handling, and species-specific reagents, especially for the studies of highly pathogenic viruses like MERS-CoV in the Biosafety Level 3 (BSL-3) laboratory. Unfortunately, common small laboratory animals like mice [16, 17] , ferrets [18] , guinea pigs [19] , and hamsters [20] are not susceptible to MERS-CoV infection because their homologous DPP4 cannot be bound and utilized by MERS-CoV as a host receptor for entry [21, 22] . Haagmans et al. detected MERS-CoV RNA in the respiratory tract of New Zealand white rabbits following inoculation but found no clinical signs of disease [23] .
Several strategies have been used to overcome this receptor incompatibility and develop mouse models of MERS-CoV infection. In 2014, we developed the first mouse model of MERS-CoV infection [24] . We delivered a recombinant adenovirus 5 encoding human DPP4 (hDPP4) to the lungs of mice. Transient expression of hDPP4 by adenovirus transduction made the mice temporarily permissive for MERS-CoV infection, but animals developed only mild lung disease. Generation of transgenic mice expressing a virus receptor is a common strategy to make mice permissive to infection. Several groups in addition to ours developed mice with transgenic expression of hDPP4 using different promoters [25] [26] [27] [28] . The disease severity following MERS-CoV infection in transgenic mice correlated with the cellular distribution and expression level of hDPP4. In transgenic mice expressing hDPP4 driven by the cytokeratin 18 promoter [26] or a ubiquitous promoter [25, 27, 28] , MERS-CoV replicates and causes respiratory disease and mortality. However, the lethality was found to be secondary to overwhelming central nervous system (CNS) disease or multiorgan damage. This was also observed in mice transgenic for human ACE2 driven by the cytokeratin 18 promoter and infected with SARS-CoV [29] . In transgenic mice expressing hDPP4 under the human surfactant protein C (SPC) promoter, which restricts expression to bronchiolar and alveolar epithelia, MERS-CoV infection caused only mild disease [26] . Thus, these transgenic mice do not reproduce a severe lung disease phenotype that resembles MERS.
Alternative strategies for the creation of mouse models of MERS-CoV infection are generation of DPP4 humanized mice and adaptation of the virus to the animals. Pascal et al. reported a model in which all of the mouse Dpp4 exons had been humanized and also generated humanized monoclonal antibodies against the MERS-CoV S protein using a novel strategy [30] . MERS-CoV infection in this model caused pulmonary edema, vascular cuffing, and alveolar septal thickening with an associated~20% weight loss, necessitating euthanasia [31] . Another MERS mouse model was engineered by changing two amino acids in the mouse Dpp4 locus using CRISPR-Cas9 technology [32] . This model supported MERS-CoV replication without severe disease. Similarly, our human DPP4 knock-in mouse model supported MERS-CoV replication but did not lead to a severe lung disease phenotype [33] . Two mouse-adapted (MA) strains of MERS-CoV were subsequently developed independently by serial passage of the HCoV-EMC/2012 strain [1] in the lungs of the two humanized mouse models [32, 33] . The resultant MERS-15 and MERS MA 6.1.2 mouse-adapted MERS-CoV strains replicated to high titers in the lungs of the CRISPR-Cas9 genetically engineered mouse model and the hDPP4 knock-in mouse model, respectively. The respiratory disease that developed in both mouse models and the associated mortality shared similarities with severe cases of MERS [32, 33] . Mouse adaptation was also successfully used to generate several SARS-CoV strains capable of modeling severe SARS-CoV lung disease in mice [34] [35] [36] . Thus, the adaption of the virus to enhance virulence in the mouse is a very useful approach to generate mouse models for coronavirus-associated lung disease.
Materials
These materials can be altered to fit the requirements for other viruses of interest.
1. HCoV-EMC/2012 strain.
2. hDPP4 knock-in mouse (C57BL/6 strain with mouse Dpp4 exons 10-12 replaced with the human codons). 
Methods
All procedures are performed under BSL-3 laboratory conditions and must follow the standard operating protocol of a BSL-3 facility and regulatory agencies. All manipulations of infectious specimens, samples, and mice must be performed within a biosafety cabinet or within a contained device such as a centrifuge.
All tissue culture media and waste must be bleached and autoclaved prior to disposal.
All instruments must be disinfected with Virex plus or 10% bleach. 4. Hold the mouse in a vertical position with the nose pointed upward (see Note 4) . Carefully pipette 50 μL of diluted virus onto the nostrils drop by drop, carefully matching the rate at which the mouse inhales (see Note 5).
Intranasal Infection

Place inoculated mouse in a 1000 mL polypropylene beaker.
Repeat until all mice are infected. Transfer mice back to their cage and monitor until they regain consciousness (see Note 6). 6. Fill a 10 mL syringe with cold sterile DPBS using a 25 g Â 5/8 inch needle. Insert the needle into the apex of the left ventricle and make a small incision in the right atrium. Slowly perfuse !5 mL cold sterile DPBS into the left ventricle. Next, insert the needle into the apex of the right ventricle and perfuse !5 mL cold sterile DPBS (see Note 10).
Evaluation of
7.
Remove the lungs and heart from the thoracic cavity. Remove the liver, kidney, spleen, and small intestine. Place organs in a small polystyrene weighing dish. Remove remaining connective tissue.
8. To harvest the brain, turn the mouse over and wet the fur of the head with 70% ethanol. Grasp the ears with forceps and cut off the skin and fur to expose the skull. Remove remaining skin at the base of the neck to further expose the skull. Immobilize the mouse and make an incision along the sagittal suture of the skull using a single edge razor blade (see Note 11) . Wedge one prong of the curved serrated forceps into the now opened sagittal suture. Slowly pry up the skull, grasp the piece of skull with forceps and peel outward to remove. Repeat on the other side. Use curved forceps to lift the brain from the skull. Place brain tissue in the small polystyrene weighing dish. 9. Carefully place each organ into a 50 mL disposable tissue grinder filled with 2 mL sterile cold DPBS for homogenization or into 2 mL of TRIzol for RNA extraction (see Note 12).
10. Grind the lung tissue and transfer the homogenates or RNA samples into 2.0 mL sterile screw-top tubes with O-ring cap (see Note 13) . Store samples at À80 C. Thaw and spin down the cell debris in lung homogenates before use. 
Repeat this process (steps 2-3).
The virulence of the virus should be evaluated in groups of mice by weight loss and survival after every 5-10 in vivo passages.
Isolation of Viral Clones
After the virulence of the virus has been significantly enhanced, single plaques of the adapted virus should be purified and evaluated.
1. Plate Vero81 cells in D10 media in 6-well plates one day before infection.
2. Rapidly thaw lung homogenates from the selected passage. Mix the lung homogenates from two mice in a 2.0 mL sterile screwtop tube with O-ring cap on ice.
3. Serially dilute the mixed lung homogenates tenfold in 2.0 mL sterile screw-top tubes with O-ring caps, using ice-cold serumfree DMEM (see Note 15) . Keep the dilutions on ice.
4. Remove the medium from each well and add diluted samples (in a volume of 400 μL) to each well.
5.
Place the plates in the 37 C incubator for 1 h and rotate gently every 15 min.
6. Melt 2% low melting point agarose and maintain in a 65 C water bath.
7. Mix overlay media and 2% low melting point agarose at a volume ratio of 1:1. Rotate the tube several times to fully mix. Overlay cells with 1.5 mL of mixed media using 10 mL stripettes.
8. Let the plates sit in the hood for~5 min at RT or until the agarose overlay turns solid. Add 0.5 mL D2 medium on the top of solidified agarose.
9. Place the plates in the 37 C incubator. 10 . After 3 days, plaques should be visible. Remove the liquid on the top of the agarose. Circle the visible plaques on the underside of the plates using a permanent marker (see Note 16).
11. Vertically penetrate the agarose and pipette the circled plaque several times with a 1 mL graduated transfer pipette. The agarose above the plaque will be pulled into the pipette. 10. Carefully keep the tip of the needle in the lumen of the ventricle. Be sure to puncture the right atrium as this will help to drain blood during the perfusion. The lung will turn white after perfusion.
11. Make sure that the incision does not exceed the thickness of the skull; avoid cutting into the brain tissue.
12. The individual organs can be divided into pieces and transferred to grinders with PBS or TRIzol separately. 13 . Lung homogenates are immediately transferred to tubes on ice. RNA samples are transferred to a tube and incubated for at least 15 min at room temperature per our BSL-3 specific standard operating procedures.
14. At 2 days post infection with 10 5 pfu/mouse, HCoV-EMC/ 2012 strain replicates in the lung of the hDPP4 KI mice to a titer of around 4 Â 10 6 pfu/mL, which equals 2 Â 10 5 pfu in 50 μL. We chose the 10 5 pfu/mouse inoculum to begin because we wanted to use a similar dose range during in vivo serial passage while skipping the titration step. 15 . Titrate the homogenates of the passage of interest and select a virus dilution that produces 10 plaques in a well. This allows identification of individual clear single plaques. 16 . Only circle the unambiguous clear single plaques.
17. Compared to Vero 81 cells, we found that the MERS-CoV RNA genome is more stable when propagated in Huh7 cells (less likely to introduce genomic deletions, insertions, or point mutations).
